FDA Classifies Post-Birth Chromosome Checker as Safe Class II Device
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting the postnatal chromosomal copy number variation detection system into a special safety category called Class II. This means the device will have clear rules to keep it safe and effective, helping patients get access to new, helpful technology faster. This change affects device makers and aims to cut red tape without compromising safety, with no extra costs announced.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Postnatal CNV Test Reclassified to Class II
The FDA is classifying the postnatal chromosomal copy number variation (CNV) detection system as Class II (special controls). The agency says the special controls will be identified in this order and codified, and that the Class II classification provides a reasonable assurance of safety and effectiveness while reducing regulatory burdens.
Faster Patient Access to CNV Tests
You may get better access to postnatal chromosomal copy number variation detection systems because the FDA says Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. The FDA also states the classification provides a reasonable assurance of safety and effectiveness.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-16031, Medical Devices; Immunology and Microbiology Devices; Classification of the Anti-Phospholipase A2 Receptor Immunological Test System
The FDA is officially putting the anti-phospholipase A2 receptor test into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get access to this important medical tool faster. Labs and device makers should get ready for these new rules, which aim to make things smoother without extra costs or delays.
Next: 2025-16033, Medical Devices; Radiology Devices; Classification of the Liver Iron Concentration Imaging Companion Diagnostic for Deferasirox
The FDA is officially classifying a special imaging device that helps doctors measure liver iron levels for patients using deferasirox as a Class II device with safety rules. This change means the device will be safer and easier to get, helping patients get better care faster. Medical device makers and patients can expect smoother approvals without extra costs or delays.